Pharmaceutical company Sandoz reported on Monday the commercial launch of Treprostinil Injection in the US PAH market, with 180 days of marketing exclusivity.

According to the company, Treprostinil is indicated for Pulmonary Arterial Hypertension (PAH), a progressive disease resulting in heart failure and shortened life expectancy. About 52,000 patients have been diagnosed with PAH in the US, with rates expected to rise due to increased survival and diagnosis rates.

Treprostinil Injection is the first fully substitutable AB rated generic version of Remodulin (treprostinil) Injection sold by United Therapeutics Corporation.

Under the terms of an agreement, Sandoz will collaborate with RareGen LLC to commercialise Treprostinil Injection, which is supplied in 20 ml multi-dose vials in four strengths:20 mg, 50 mg, 100 mg, or 200 mg (1 mg/ml, 2.5 mg/ml, 5 mg/ml or 10 mg/ml). RareGen LLC is backed by PBM Capital Group, a healthcare investor.

In FY 2018, the global sales for Treprostinil were approximately USD599m, according to United Therapeutics Corporation.